Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799795 | 1.00 | MME (0.50) | MMEACECYP2C9PTGS2ACE2 | |
| SCHEMBL5981504 | 0.90 | HDAC3 (0.44) | MMEACEKIF11CYP1A2CYP2C19 | |
| SCHEMBL88835 | 0.90 | HDAC3 (0.44) | MMEACEKIF11CYP1A2CYP2C19 | |
| SCHEMBL6670650 | 0.84 | HDAC1 (0.44) | NPC1RAB9AKIF11 | |
| SCHEMBL6670653 | 0.84 | HDAC1 (0.44) | NPC1RAB9AKIF11 | |
| SCHEMBL6674793 | 0.83 | MAPT (0.42) | NPC1RAB9AKIF11GAA | |
| SCHEMBL20732297 | 0.83 | ESR1 (0.42) | MMEACEKIF11 | |
| SCHEMBL6674790 | 0.83 | MAPT (0.42) | NPC1RAB9AKIF11GAA | |
| SCHEMBL6674976 | 0.81 | POLB (0.45) | CYP2C9NPC1RAB9AKIF11CYP1A2 | |
| SCHEMBL6801098 | 0.81 | MME (0.40) | MMENPC1RAB9AKIF11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | MME 127/4885ACE 241/4885CYP2C9 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.